EGFR and non-small cell lung carcinoma: At the 21st World Conference on Lung Cancer (WCLC) in 2020, the results of a phase II SUMMIT basket study revealed that pretreated NSCLC patients with EGFR exon 18 mutations had an objective response rate (ORR) of 40% and a duration of response (DoR) of 7.5 months to neratinib, and the ORR and DoR were better than those of other EGFR-TKIs in previous studies (17).